| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LPAR3 |
| Uniprot No | Q9UBY5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 298-353aa |
| 氨基酸序列 | EDMYGTMKKMICCFSQENPERRPSRIPSTVLSRSDTGSQYIEDSISQGAVCNKSTS |
| 预测分子量 | 11.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LPAR3重组蛋白的3篇文献摘要示例(文献信息为虚拟示例，供参考)：
1. **标题**：*Structural characterization of recombinant human LPAR3 and its ligand binding mechanism*
**作者**：Smith J, et al.
**摘要**：通过重组表达纯化人源LPAR3蛋白，利用X射线晶体学解析其三维结构，揭示了溶血磷脂酸(LPA)结合位点的关键氨基酸残基及受体激活的构象变化。
2. **标题**：*Functional analysis of LPAR3 in cancer cell migration using recombinant receptor mutants*
**作者**：Li X, et al.
**摘要**：构建LPAR3重组突变体(HEK293细胞表达)，发现其通过Gα12/13-Rho信号通路调控肿瘤细胞迁移，为靶向LPAR3的癌症治疗提供依据。
3. **标题**：*Development of a high-yield LPAR3 recombinant protein production system in insect cells*
**作者**：Garcia R, et al.
**摘要**：优化杆状病毒-昆虫细胞表达系统，实现LPAR3重组蛋白的高效表达与纯化，用于高通量药物筛选及抗体开发。
(注：以上文献为示例，实际研究中建议通过PubMed或Sci-Hub等平台以“LPAR3 recombinant”、“lysophosphatidic acid receptor 3 expression”等关键词检索近期论文。)
**Background of LPAR3 Recombinant Protein**
Lysophosphatidic acid receptor 3 (LPAR3), a member of the G protein-coupled receptor (GPCR) family, binds lysophosphatidic acid (LPA)—a bioactive lipid mediator involved in diverse cellular processes. LPAR3 activation triggers intracellular signaling cascades (e.g., via Gαi/o, Gαq/11. or Gα12/13 proteins), regulating cell proliferation, migration, survival, and cytoskeletal dynamics. It is implicated in physiological and pathological conditions, including cancer progression, fibrosis, inflammation, and reproductive system regulation.
Recombinant LPAR3 protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or insect cells (e.g., Sf9), which enable proper post-translational modifications (e.g., glycosylation) critical for receptor functionality. This recombinant form retains ligand-binding and signaling properties, making it a vital tool for studying LPAR3-specific pathways and screening therapeutic agents.
Research highlights LPAR3's role in diseases such as ovarian and breast cancers (promoting metastasis), pulmonary fibrosis (activating fibroblasts), and endometriosis (mediating cell invasion). Recombinant LPAR3 facilitates drug discovery by serving as a target for antagonists or agonists, potentially modulating disease pathways. For example, small-molecule inhibitors targeting LPAR3 are being explored to curb cancer cell invasion or fibrotic tissue remodeling.
Challenges in working with recombinant LPAR3 include maintaining structural stability and membrane localization, often addressed using detergents or lipid-based systems during purification. Despite these hurdles, its applications in structural biology (e.g., cryo-EM studies) and high-throughput assays underscore its importance in advancing precision medicine.
In summary, LPAR3 recombinant protein is a cornerstone for decoding LPA-driven mechanisms and developing targeted therapies across multiple disease areas.
×
